This company listing is no longer active
HEXO Resultados de beneficios anteriores
Pasado controles de criterios 0/6
HEXO's earnings have been declining at an average annual rate of -42.2%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 39.8% per year.
Información clave
-42.2%
Tasa de crecimiento de los beneficios
-4.5%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals | 6.0% |
Tasa de crecimiento de los ingresos | 39.8% |
Rentabilidad financiera | -191.4% |
Margen neto | -220.1% |
Última actualización de beneficios | 30 Apr 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Hexo to produce Mike Tyson's cannabis brand's products in Canada
Aug 30Canopy Growth, Tilray other Canadian cannabis names up amid WallStreetBets chatter
Aug 17HEXO receives additional 180 calendar day grace period for regaining compliance
Jul 28HEXO wins shareholder approval for note transaction with Tilray
Jul 05HEXO: Undervalued, But With Certain Dilution Risks
Apr 28HEXO Q1 Earnings: Not A Great Path Forward
Dec 14Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero HEXO. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Apr 23 | 124 | -273 | 61 | 1 |
31 Jan 23 | 148 | -301 | 86 | 1 |
31 Oct 22 | 177 | -1,013 | 105 | 3 |
31 Jul 22 | 191 | -1,074 | 122 | 3 |
30 Apr 22 | 187 | -1,042 | 128 | 4 |
31 Jan 22 | 164 | -918 | 109 | 4 |
31 Oct 21 | 144 | -228 | 96 | 4 |
31 Jul 21 | 124 | -115 | 80 | 4 |
30 Apr 21 | 112 | -214 | 75 | 4 |
31 Jan 21 | 112 | -213 | 75 | 4 |
31 Oct 20 | 96 | -491 | 78 | 4 |
31 Jul 20 | 81 | -546 | 91 | 5 |
30 Apr 20 | 69 | -423 | 115 | 7 |
31 Jan 20 | 60 | -411 | 119 | 6 |
31 Oct 19 | 56 | -117 | 114 | 5 |
31 Jul 19 | 48 | -70 | 105 | 3 |
30 Apr 19 | 34 | -35 | 73 | 0 |
31 Jan 19 | 22 | -30 | 54 | 0 |
31 Oct 18 | 9 | -34 | 41 | 0 |
31 Jul 18 | 5 | -23 | 23 | 0 |
30 Apr 18 | 4 | -12 | 15 | 0 |
31 Jan 18 | 4 | -22 | 12 | 0 |
31 Oct 17 | 4 | -14 | 9 | 0 |
31 Jul 17 | 4 | -12 | 7 | 0 |
30 Apr 17 | 4 | -15 | 7 | 0 |
31 Jan 17 | 4 | -3 | 5 | 0 |
31 Oct 16 | 3 | -3 | 4 | 0 |
31 Jul 16 | 2 | -3 | 4 | 0 |
31 Jul 15 | 0 | -3 | 2 | 0 |
Ingresos de calidad: HEXO is currently unprofitable.
Margen de beneficios creciente: HEXO is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: HEXO is unprofitable, and losses have increased over the past 5 years at a rate of 42.2% per year.
Acelerando crecimiento: Unable to compare HEXO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: HEXO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.3%).
Rentabilidad financiera
Alta ROE: HEXO has a negative Return on Equity (-191.4%), as it is currently unprofitable.